On Ozempic or Mounjaro? What your data reveals about GLP-1 weight loss
GLP-1 medications like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) drive fast weight loss, and that whole-body shift shows up in the signals your Oura Ring already tracks — resting heart rate, heart-rate variability, body temperature and sleep. None of it is a substitute for your prescriber, but reading these trends against your own baseline tells you whether the loss is going the way you want.
On this page
Resting heart rate usually drops — but can spike early
As body weight comes down, resting heart rate (RHR) tends to fall over the months, because a lighter body asks less of the heart at rest. The catch is the early phase: GLP-1 drugs have a documented, modest heart-rate-raising effect, and dehydration from reduced appetite, nausea or low food intake can push your overnight RHR up for days at a time. So a higher reading in the first weeks is common and usually settles — but a persistent, unexplained climb is worth raising with your doctor.
HRV reflects how well you're fuelling the deficit
Heart-rate variability is sensitive to under-eating, dehydration and the physical stress of rapid loss. If you cut intake hard and skimp on protein, fluids or electrolytes, you'll often see your HRV baseline sag and recovery scores soften. Smoother, well-fuelled loss tends to keep HRV closer to your normal range. Because HRV is deeply individual, the signal isn't an absolute number — it's the direction of your own rolling average while you're on the drug.
The real risk: losing muscle with the fat
The biggest danger with GLP-1 loss isn't the scale moving too slowly — it's losing lean muscle along with fat when the deficit is steep and protein is low. Your ring can't measure muscle directly, but a falling weight paired with stalling activity, dropping strength and a slumping HRV is the pattern to avoid. Keeping resistance training in, prioritising protein, and losing at a sane pace (roughly 0.5–1% of body weight a week) protects the muscle that keeps your metabolism up.
Sleep and temperature shift too
Many people sleep differently on GLP-1 drugs — sometimes better as weight comes off and apnea-type disruption eases, sometimes worse early on from nausea or late meals sitting heavy. Body temperature can read low on nights you've eaten very little. None of these alone is alarming, but together they explain why your readiness might wobble in the first month even though the scale is moving.
Vitra turns this into something you can actually watch: it tracks weight, BMI, estimated body-fat and your TDEE alongside your Oura RHR, HRV and sleep, and its tag-correlation engine lets you mark the days that matter — a dose change, a low-food day, a strength session — to see how each moves your numbers. Everything is computed locally from your Oura data, with nothing sent to the cloud.
Frequently asked questions
- Wilding et al. (2021), New England Journal of Medicine (STEP 1): once-weekly semaglutide 2.4 mg gave a mean 14.9% body-weight reduction at 68 weeks against 2.4% on placebo, in 1,961 adults
- Spiegel et al. (2004), Annals of Internal Medicine: two nights at four hours cut leptin 18%, raised ghrelin 28%, and increased hunger 24%
Pedro Thomaz builds Vitra, a desktop app that reads Oura data against your own baseline instead of a population average. He has worn a ring daily for years and reads these same numbers every morning — which is where most of what is written here comes from. Vitra is not a medical device and nothing on this blog is medical advice.
Local AI on your Mac or PC. One-time purchase, 7-day trial, no Vitra subscription.
Download Vitra →